Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD19 CAR-CD8alpha-CD28-CD3zeta T cells KYV 101

A preparation of autologous CD4- and CD8-positive T cells that are transduced with a lentiviral vector encoding for a chimeric antigen receptor (CAR) consisting of a human single chain variable fragment (scFv) of anti-CD19 and fused to the hinge and transmembrane domains of CD8alpha co-receptor, the cytoplasmic costimulatory domain of human CD28, and the T-cell antigen receptor complex zeta chain (CD3-zeta), with potential immunostimulating activity. Upon transfusion, autologous anti-CD19 CAR-CD8alpha-CD28-CD3zeta T cells KYV 101 recognize and induce selective toxicity and lysis in CD19-expressing B-cells. CD19, a B-cell-specific cell surface antigen, is overexpressed in B-cell lineage malignancies and in certain B-cell-driven autoimmune diseases.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CD19 CAR T cells KYV 101
autologous anti-CD19 CAR-T cells KYV 101
Code name:KYV 101
KYV-101
KYV101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search